Paragonix Technologies
Paragonix Technologies develops FDA-cleared and CE-marked controlled hypothermic organ preservation devices for heart, lung, liver, pancreas, and kidney transplantation, serving transplant centers and Organ Procurement Organizations with a digital tracking platform and 24/7 clinical support; the company operates as a subsidiary of Getinge AB following its September 2024 acquisition.
- Company typePrivate
- Founded2018
- HeadquartersNorth Waltham, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Paragonix Technologies does
Paragonix Technologies is a US-based medical device company specializing in advanced organ preservation and transport systems for solid organ transplantation. Founded in 2010 (with commercial operations beginning in 2018) and headquartered in Waltham, Massachusetts, the company sells a portfolio of six FDA-cleared and five CE-marked preservation devices covering heart (SherpaPak), lung (LUNGguard and BAROguard), liver (LIVERguard), pancreas (PancreasPak), and kidney (KidneyVault) to transplant centers and federally designated Organ Procurement Organizations (OPOs). The underlying technology replaces traditional ice-based transport with controlled hypothermic preservation maintaining organs at 4-8°C to prevent freezing injury, combined with a digital platform (Paragonix App and Web Portal) that provides real-time GPS tracking, temperature monitoring, and HIPAA-compliant case messaging.
The company's commercial ecosystem is reinforced by 24/7 clinical procurement services, a nationwide distribution fleet, seven procurement hubs staffed by 50+ clinical specialists, and the GUARDIAN clinical registries (Heart, Lung, Liver) — described as the largest observational database studying post-transplant impact of organ preservation. Business model is primarily direct enterprise sales of hardware devices to transplant centers and OPOs through quote-based multi-year agreements, complemented by clinical support services and managed logistics. Following its September 2024 acquisition by Swedish medical technology conglomerate Getinge AB for approximately USD 477 million, Paragonix operates as a Getinge subsidiary, gaining access to global distribution infrastructure while maintaining its product brand identity and clinical focus.
Paragonix Technologies firmographics
Firmographics- Name
- Paragonix Technologies
- Legal name
- PARAGONIX TECHNOLOGIES, INC.
- Website
- https://paragonixtechnologies.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Paragonix Technologies develops FDA-cleared and CE-marked controlled hypothermic organ preservation devices for heart, lung, liver, pancreas, and kidney transplantation, serving transplant centers and Organ Procurement Organizations with a digital tracking platform and 24/7 clinical support; the company operates as a subsidiary of Getinge AB following its September 2024 acquisition.
- Ownership category
- akta.pro rank
Paragonix Technologies industry classification
Industry- Product category
- Medical Devices - Organ Preservation and Transport
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)
Keywords
Where Paragonix Technologies is headquartered
LocationHeadquarters
- HQ city
- North Waltham
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Paragonix Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Organ Preservation Devices: Sale of FDA-cleared and CE-marked organ preservation devices including SherpaPak, LUNGguard, LIVERguard, BAROguard, PancreasPak, and KidneyVault for cardiothoracic and abdominal transplantation
- Clinical Support Services: 24/7 clinical support services provided nationwide including on-call procurement support and clinical coordination for transplant centers
- Distribution Fleet Services: Dedicated fleet providing organ preservation technology, logistics, and clinical expertise at point of care across the United States
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise pricing for transplant centers and OPOs |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels7 records
Paragonix Technologies product offering
Product offeringCore offering
Paragonix Technologies manufactures and sells FDA-cleared and CE-marked medical devices for Advanced Organ Preservation during donor organ transport, including SherpaPak (cardiac), LUNGguard and BAROguard (lung), LIVERguard (liver), PancreasPak (pancreas), and KidneyVault (kidney). The devices maintain controlled hypothermic temperatures (4-8°C) to prevent cold injury, and are complemented by a proprietary digital tracking platform (Paragonix App and Web Portal) and 24/7 clinical procurement support services sold to transplant centers and Organ Procurement Organizations.
Product overview
Paragonix Technologies offers a comprehensive Advanced Organ Preservation ecosystem consisting of six FDA-cleared and five CE-marked medical devices for cardiothoracic and abdominal organ transplantation. The core product portfolio includes SherpaPak® (cardiac), LUNGguard® and BAROguard® (lung), LIVERguard® (liver), PancreasPak™ (pancreas), and KidneyVault® (kidney) preservation systems. These devices maintain consistent controlled hypothermic temperatures to prevent organ freezing during transport. The product ecosystem is complemented by a proprietary digital platform (Paragonix App and Web Portal) providing real-time GPS tracking, temperature monitoring, and case coordination, supported by 24/7 clinical procurement services and the GUARDIAN clinical registries—the world's largest observational database for organ preservation outcomes research.
Differentiator
Problem solved
Functional benefit
Brands
- SherpaPak: Cardiac Transport System - FDA-cleared and CE-marked heart preservation device
- LUNGguard
- BAROguard
- LIVERguard
- PancreasPak
- KidneyVault
Products and services
- SherpaPak Cardiac Transport System FDA-cleared and CE-marked heart preservation device that maintains donor hearts at controlled hypothermic temperatures (4-8°C) during transport. Features TempLock thermal control technology and is intended for up to 4 hours of static hypothermic preservation.
- LUNGguard Organ Preservation System FDA-cleared and CE-marked lung preservation device that maintains donor lungs at controlled hypothermic temperatures during transport. Intended for up to 8 hours of static hypothermic preservation.
- BAROguard Donor Lung Preservation System FDA-cleared and CE-marked next-generation lung preservation device combining advanced hypothermic preservation with automated continuous active airway pressure control. Maintains optimal temperature and clinically recommended inflation pressure for donor lungs throughout transport. Recognized on TIME's 2024 Best Inventions List.
- LIVERguard Donor Liver Preservation System FDA-cleared and CE-marked liver preservation device for static hypothermic preservation of donor livers during transportation. Intended for up to 15 hours of preservation time.
- PancreasPak Organ Preservation System FDA-cleared organ preservation system for donor pancreas transportation. Can maintain donor organ storage temperature between 4°C and 8°C through 21 hours.
- KidneyVault Portable Renal Perfusion System FDA-cleared pulsatile hypothermic machine perfusion system for kidney preservation and transportation. Can maintain donor kidney storage temperature between 4°C and 8°C through 24 hours. Reached 1,000 clinical cases milestone in March 2026.
- Paragonix Digital Hub & App Mobile application and web portal providing real-time tracking of organ location via GPS, temperature monitoring, HIPAA-compliant messaging for case coordination, and access to historical case data and trends.
- Clinical Procurement Services 24/7 clinical support services providing on-call procurement or support customized to transplant center needs. Includes nationwide network of experienced clinical specialists and organ procurement teams.
- Paragonix Distribution Fleet Nationwide supply chain initiative featuring dedicated fleet vehicles to improve access to organ preservation technologies and clinical support. Vehicles deployed in Florida and California.
Quantifiable outcome
- 67% reduction in Severe Primary Graft Dysfunction (PGD) in heart transplant patients using SherpaPak vs. conventional ice storage (p=0.011)
- +5 more outcomes
Companies that use Paragonix Technologies
Customer profileNamed customers16 records
Segments5 records
Ideal customer profiles4 records
Paragonix Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature10 records
Paragonix Technologies partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered major, strategic and core.
- UW MedicinemajorCollaboration announced May 2026 to launch the CONCERT-DCD clinical trial aimed at maximizing heart transplant utilization through donation after circulatory death (DCD) donor hearts. University of Washington serving as clinical trial sponsor.
- Gravitas SurgicalmajorStrategic partnership announced November 2025 to enhance donor lung preservation and viability on the US West Coast. Coincided with Gravitas's launch of an Ex Vivo Lung Perfusion program in Phoenix, Arizona. Collaboration aims to improve transplant success rates and expand access to lung transplants in the Western United States.
- Tennessee Donor ServicesstrategicOPO partnership supporting Paragonix's 100th kidney transplant case with FDA-cleared KidneyVault system. Tennessee Donor Services serves over 6 million people across Tennessee and Virginia.
- Donor Network WestmajorStrategic partnership announced September 2025 to enhance clinical utilization of complex donor kidneys via the Paragonix KidneyVault Portable Renal Perfusion System. Federally designated OPO serving California and Nevada.
- Tampa General Hospital Transplant InstitutemajorPartnership supporting groundbreaking kidney transplant case with KidneyVault system maintaining continuous perfusion over 30 hours with total cold ischemic time exceeding 46 hours. Demonstrates technology's capability with medically complex donor kidneys.
- Sierra Donor Services and UCI HealthstrategicGroundbreaking initiative to place high-risk donor kidneys, expanding transplant opportunities for patients in need. Combines Sierra Donor Services OPO expertise with UCI Health transplant program and Paragonix KidneyVault technology.
- HonorBridgestrategicNorth Carolina's largest organ donation and tissue recovery organization partnered with Paragonix for first successful liver transplant using LIVERguard technology. HonorBridge facilitated donor liver transport from North Carolina to Tampa General Hospital.
- GetingecoreGetinge acquired Paragonix Technologies for approximately USD 477 million in September 2024, marking Getinge's entry into the organ preservation and transportation market. The acquisition aims to expand Getinge's portfolio and leverage Paragonix's strong growth and innovative products. Paragonix operates as a Getinge company following the acquisition.
- Nationwide Organ Recovery Transport Alliance (NORA)strategicLaunch of new donor organ courier service in partnership with NORA to establish cost-effective transport alternative. Combines Paragonix preservation technology with NORA's logistics expertise.
- University of Nebraska Medical CentermajorCollaboration on novel NRP-DCD (Normothermic Regional Perfusion - Donation After Circulatory Death) method to expand organ donor pool. Combines UNMC's NRP technique with Paragonix SherpaPak for DCD heart recovery and transport. IRB approved study registered with NIH (NCT05038943).
Scale indicators14 records
Recent moves8 records
Expansion highlights6 records
Paragonix Technologies competitors and assessment
Company assessmentDirect peers
- TransMedics Group: TransMedics develops the Organ Care System (OCS), a normothermic machine perfusion platform for heart, lung, and liver preservation. It is the most direct competitor to Paragonix in multi-organ transplant preservation, with both companies targeting the same transplant centers and OPOs with fundamentally different preservation approaches.
- Organ Recovery Systems: Organ Recovery Systems manufactures the LifePort Kidney Transporter, a hypothermic machine perfusion device for donor kidneys. It is the most direct competitor to Paragonix's KidneyVault in the kidney preservation segment and shares the hypothermic perfusion paradigm.
- XVIVO Perfusion: XVIVO Perfusion (Sweden) develops organ preservation and perfusion solutions, most notably for lung transplantation (Lung Assist), and has expanded into heart and liver perfusion. As a European competitor with overlapping transplant indications, XVIVO is a relevant comparable in international markets.
- OrganOx: OrganOx (UK) developed the metra normothermic liver perfusion device, a direct alternative to Paragonix's LIVERguard for liver preservation. Both companies compete in the advanced liver preservation market with different technology approaches (normothermic vs. static hypothermic).
Emerging players
- Bridge to Life: Bridge to Life manufactures cold storage and machine perfusion solutions for organ preservation, including Belzer UW Cold Storage and LifeCradle perfusion devices. It competes primarily in traditional cold storage and represents a lower-cost alternative to Paragonix's controlled hypothermic technology.
- Institut Georges Lopez (IGL): IGL produces preservation solutions (e.g., IGL-1, SCOT 30) and perfusion devices used in organ transplantation. It is a European-headquartered competitor offering both solutions and equipment, partially overlapping with Paragonix's perfusion/preservation offering.
- Preservation Solutions: Preservation Solutions manufactures cold storage organ preservation solutions (e.g., Euro-Collins, Custodiol HTK). It is a niche player in the broader organ preservation ecosystem and an indirect competitor as it supplies the traditional ice-based cold storage workflow that Paragonix devices aim to replace.
- Global Transplant Solutions: Global Transplant Solutions manufactures the LifePort disposable perfusion circuits and related organ transport products. It is an emerging competitor in the kidney and broader organ preservation equipment space with direct overlap to Paragonix's perfusion product line.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Paragonix Technologies social profiles
Digital presenceParagonix Technologies compliance and trust
Trust signalCompliance6 records
Paragonix Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Paragonix Technologies leadership team
Management profileNumber of profiles
Profiles10 records
Paragonix Technologies funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Paragonix Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Paragonix Technologies
What does Paragonix Technologies do?
Paragonix Technologies manufactures and sells FDA-cleared and CE-marked medical devices for Advanced Organ Preservation during donor organ transport, including SherpaPak (cardiac), LUNGguard and BAROguard (lung), LIVERguard (liver), PancreasPak (pancreas), and KidneyVault (kidney). The devices maintain controlled hypothermic temperatures (4-8°C) to prevent cold injury, and are complemented by a proprietary digital tracking platform (Paragonix App and Web Portal) and 24/7 clinical procurement support services sold to transplant centers and Organ Procurement Organizations.
Is Paragonix Technologies a public or private company?
Paragonix Technologies is a private company. It is classified as corporate owned and is currently acquired.
When was Paragonix Technologies founded?
Paragonix Technologies was founded in 2018. It employs 51 to 100 people.
Where is Paragonix Technologies based?
Paragonix Technologies is headquartered in North Waltham, United States, in the North America region.
How does Paragonix Technologies make money?
Three revenue lines are on record. Organ Preservation Devices are the primary driver. The others are clinical Support Services and distribution Fleet Services.
Who are Paragonix Technologies's main competitors?
Direct peers on record are TransMedics Group, Organ Recovery Systems, XVIVO Perfusion and OrganOx. Emerging players are Bridge to Life, Institut Georges Lopez (IGL), Preservation Solutions and Global Transplant Solutions.
Does Paragonix Technologies have an API?
No public API is recorded for Paragonix Technologies.
What industry is Paragonix Technologies in?
Paragonix Technologies's product category is Medical Devices - Organ Preservation and Transport. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO). Its NAICS code is 334510 and its SIC code is 3845.